SCHEMBL16166284

SCHEMBL16166284

O=C1C[C@]2(C(=O)Nc3ccc(C(F)(F)F)cc32)c2cnn(Cc3ccc(Cl)cc3)c2N1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.36
NPBWR1 P48145 2/20 0.35
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
LMNA P02545 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
RAF1 P04049 1/20 0.33
KCNQ3 O43525 1/20 0.33
KCNQ2 O43526 1/20 0.33
KCNQ4 P56696 1/20 0.33
KCNMA1 Q12791 1/20 0.33
KCNQ5 Q9NR82 1/20 0.33
P2RX3 P56373 1/20 0.33
MIF P14174 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16175824 0.95 HTR2C (0.37) AKR1B1NPBWR1HTR2CHTR2BRAF1
SCHEMBL16166745 0.94 ELOVL6 (0.37) AKR1B1NPBWR1HTR2CHTR2BKCNQ3
SCHEMBL16175842 0.89 AKR1B1 (0.36) AKR1B1KCNQ3KCNQ2KCNQ4KCNMA1
SCHEMBL16166401 0.89 AKR1B1 (0.40) AKR1B1HTR2CHTR2B
SCHEMBL16166247 0.89 AKR1B1 (0.40) AKR1B1HTR2CHTR2B
SCHEMBL16166741 0.88 AKR1B1 (0.37) AKR1B1HTR2CHTR2B
SCHEMBL16166855 0.88 NPBWR1 (0.39) AKR1B1NPBWR1HTR2CHTR2BRAF1
SCHEMBL16175839 0.86 AKR1B1 (0.36) AKR1B1KCNQ3KCNQ2KCNQ4KCNMA1
SCHEMBL16166210 0.86 KCNT1 (0.39) AKR1B1
SCHEMBL16166681 0.85 AKR1B1 (0.37) AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014167528-A1 SPIROPYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF VIRAL INFECTIONS NOVARTIS AG (CH) 2014-10-16 WO disclosed
WO-2014167528-A1 SPIROPYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF VIRAL INFECTIONS NOVARTIS AG (CH) 2014-10-16 WO disclosed